These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 37410453)
1. Recent advances in anaplastic thyroid cancer management. Hamidi S; Maniakas A Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):259-264. PubMed ID: 37410453 [TBL] [Abstract][Full Text] [Related]
2. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. Hamidi S; Dadu R; Zafereo ME; Ferrarotto R; Wang JR; Maniakas A; Gunn GB; Lee A; Spiotto MT; Iyer PC; Sousa LG; Akhave NS; Ahmed S; Learned KO; Lu C; Lai SY; Williams M; Hosseini SM; Busaidy NL; Cabanillas ME JAMA Oncol; 2024 Sep; 10(9):1264-1271. PubMed ID: 38990526 [TBL] [Abstract][Full Text] [Related]
3. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771 [No Abstract] [Full Text] [Related]
4. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease. Califano I; Smulever A; Jerkovich F; Pitoia F Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897 [TBL] [Abstract][Full Text] [Related]
5. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020 [No Abstract] [Full Text] [Related]
6. Combination Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898 [No Abstract] [Full Text] [Related]
7. Current picture of anaplastic thyroid cancer patients' care and meetable needs: A survey of 94 Institutions from the EORTC Endocrine and Head and Neck Cancer Groups. Locati LD; Colombo E; Dedecjus M; de la Fouchardière C; Sents W; Bongiovanni M; Netea-Maier R Eur J Cancer; 2023 Feb; 180():146-154. PubMed ID: 36599182 [TBL] [Abstract][Full Text] [Related]
8. Case report: Complete response of an anaplastic thyroid carcinoma patient with Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S Front Immunol; 2023; 14():1178682. PubMed ID: 37122752 [TBL] [Abstract][Full Text] [Related]
9. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area. Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298 [TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171 [No Abstract] [Full Text] [Related]
11. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Sandulache VC; Williams MD; Lai SY; Lu C; William WN; Busaidy NL; Cote GJ; Singh RR; Luthra R; Cabanillas ME Thyroid; 2017 Jan; 27(1):81-87. PubMed ID: 27785980 [TBL] [Abstract][Full Text] [Related]
12. Mutation based approaches to the treatment of anaplastic thyroid cancer. McCrary HC; Aoki J; Huang Y; Chadwick B; Kerrigan K; Witt B; Hunt JP; Abraham D Clin Endocrinol (Oxf); 2022 May; 96(5):734-742. PubMed ID: 35067961 [TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy. Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068 [TBL] [Abstract][Full Text] [Related]
14. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma. Chen TY; Lorch JH; Wong KS; Barletta JA Histopathology; 2020 Aug; 77(2):314-320. PubMed ID: 32428249 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant treatment with lenvatinib and pembrolizumab in a Barbaro D; Forleo R; Profilo MA; Lapi P; Giani C; Torregrossa L; Macerola E; Materazzi G Front Endocrinol (Lausanne); 2024; 15():1389294. PubMed ID: 39045273 [TBL] [Abstract][Full Text] [Related]
16. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres. Lorimer C; Cheng L; Chandler R; Garcez K; Gill V; Graham K; Grant W; Sardo Infirri S; Wadsley J; Wall L; Webber N; Wong KH; Newbold K Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):e60-e66. PubMed ID: 36379836 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Cabanillas ME; Ferrarotto R; Garden AS; Ahmed S; Busaidy NL; Dadu R; Williams MD; Skinner H; Gunn GB; Grosu H; Iyer P; Hofmann MC; Zafereo M Thyroid; 2018 Jul; 28(7):945-951. PubMed ID: 29742974 [TBL] [Abstract][Full Text] [Related]
18. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Charles RP; Silva J; Iezza G; Phillips WA; McMahon M Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis. Priantti JN; Rodrigues NMV; de Moraes FCA; da Costa AG; Jezini DL; Heckmann MIO Endocrine; 2024 Oct; 86(1):284-292. PubMed ID: 38709445 [TBL] [Abstract][Full Text] [Related]